These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28834469)

  • 1. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
    Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
    N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
    Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
    PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Intensive Blood Pressure Management.
    Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
    JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension.
    Liao CT; Toh HS; Sun L; Yang CT; Hu A; Wei D; Melgarejo J; Zhang ZY
    JAMA Netw Open; 2023 Feb; 6(2):e230708. PubMed ID: 36848091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
    Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Intensive Versus Standard Blood Pressure Treatment in Older Patients With Hypertension in China.
    Fan J; Zheng W; Liu W; Xu J; Zhou L; Liu S; Bai J; Qi Y; Huang W; Liu K; Cai J
    Hypertension; 2022 Nov; 79(11):2631-2641. PubMed ID: 36177835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
    Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
    Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
    ; Lewis CE; Fine LJ; Beddhu S; Cheung AK; Cushman WC; Cutler JA; Evans GW; Johnson KC; Kitzman DW; Oparil S; Rahman M; Reboussin DM; Rocco MV; Sink KM; Snyder JK; Whelton PK; Williamson JD; Wright JT; Ambrosius WT
    N Engl J Med; 2021 May; 384(20):1921-1930. PubMed ID: 34010531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
    Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops.
    Bryant KB; Moran AE; Kazi DS; Zhang Y; Penko J; Ruiz-Negrón N; Coxson P; Blyler CA; Lynch K; Cohen LP; Tajeu GS; Fontil V; Moy NB; Ebinger JE; Rader F; Bibbins-Domingo K; Bellows BK
    Circulation; 2021 Jun; 143(24):2384-2394. PubMed ID: 33855861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients.
    Stam-Slob MC; van der Graaf Y; Greving JP; Dorresteijn JA; Visseren FL
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28214794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
    Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
    Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
    Grover S; Coupal L; Lowensteyn I
    Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
    Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
    Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
    Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
    Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.